We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. While we may pursue an initial business combination target in any stage of its corporate evolution or in any industry or sector, we […]

(Note: Not an IPO. This is a Canadian electric bus manufacturer’s step-up listing in the U.S. to the NASDAQ. Our common shares are listed on the TSX Venture Exchange in Canada under the symbol “GPV” and quoted on the OTC Markets Group’s OTCQB under the symbol “GPVRF.”) From the prospectus: Although this is our initial […]

  While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on industries that align with the background of our sponsor and Industry Advisors. These industries include the technology, healthcare, consumer, industrials and hospitality & entertainment sectors, which we refer to as our targeted sectors.

While we may pursue an initial business combination target in any business, industry or geographical location, we intend to focus our search within the consumer internet, digital media and marketing technology sectors. We intend to capitalize on the ability of our management team to identify, acquire and operate a business or businesses that can benefit […]

We intend to focus our search on target businesses with enterprise values of approximately $750 million to $2.5 billion.  Our sponsor is controlled by affiliates of Nicholas J. Singer, our chairman and CEO, and Purchase Capital LLC, an investment firm founded by Mr. Singer. Purchase Capital serves as Mr. Singer’s family office and sponsor to […]

Prospective targets will include companies with global emerging growth and aggregate enterprise values of about $300 million to $1.5 billion. (Note: Growth Capital Acquisition Corp. upsized its IPO at pricing to 15 million units, up from its reduced size of 12.5 million in the amended prospectus, at $10 each to raise $150 million. The amount […]

  We are a pharmaceutical company based in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (“TCMD”) products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. We have registered and obtained approval for 26 varieties […]

We are a newly organized blank check company. While we may pursue an initial business combination in any sector, we intend to focus our efforts on businesses in the financial technology segment of the broader financial services industry, where we believe our management team’s expertise will provide us with a competitive advantage.

We intend to focus our search on companies in the life sciences industry. We are led by Dr. Samuel P. Wertheimer, Brookline’s senior scientific advisor and formerly a private equity partner in the private equity group at OrbiMed Advisors.  Our sponsor is an affiliate of Brookline Capital Markets, a division of Arcadia Securities, LLC, which we refer […]

  We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue an initial business combination target in any industry, sector […]